LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

"The collaborative approach facilitated by the agreement will allow for the most effective commercialisation of the technology."

Just as it has with Sirco! :o(

Hey Toya...you've come out of the closit......

Mistress T! .... what a pleasure, as one might say!!

Hi cynic and bb - glad you two are still keeping your eyes on all this. I'm not spending much time trading these days - just having the odd 'punt' but mainly holding longer term. Good job I didn't cling onto these too long - though they may turn around eventually I guess.

a rare positive day here with heavy volume too, but as in the past, don't be surprised to see it all disappear back down the plughole

strange things look to be happening here ...... rise is FA in monetary terms but it has been in/out of auction 2/3/4 times already ..... no news that i have seen

Probally another occassion where the PI is not privy to info til tommorow. in this case monday!!

Sold out the other week at a loss......just waited for me to do so (:(((

www.relaxzenshots.com/products/day-flight

just for info - avr volume is 4m pd and already 7.5m

From Stockopedia today:

This week at Stockopedia Central we spoke to Stephen Moon, the chief executive of functional and medical food group Provexis plc a company whose share capital is 70 per cent held by private investors. Like many science-based small-caps, Provexis and its shareholders have had to wait several years for product development to reach the all-important licensing stage. Some nifty footwork around tough new EU regulations and a novel profit-sharing alliance with a major distributor look to have sealed a bright future for the company. That just leaves the companys CEO to begin developing a pipeline of new product candidates to capitalise on that success.
Edit plus: all eyes will be on Provexis in June when it reports in financial

A PXS rns but looks like for the wrong reasons.....losses.,.

Jun 17 2011
0ShareAdd a commentRecommend PROVEXIS, the health supplements developer, reported deeper losses for the year to March 31, today alongside better revenues and the acquisition of a profitable sports nutrition manufacturer.

A 2.5m share placing will help fund the 8m takeover of Blackburn-based SiS (Science in Sport) which produces sports nutrition products for professional and elite athletes, including Olympians and professional cyclists and triathletes.

Provexis, which has a research and development (R&D) base in Liverpools Crown Street, benefited from the commercial launch of its first heart-health product, Fruitflow, in the UK and US.

Turnover rose from 14,767 to 50,086.

However, R&D costs increased from 718,468 to 1.26m, and while administrative costs were reined in from 1.18m to 1.27m, the company made a loss before tax of 2.34m compared with 1.7m last year.

However, chief executive Stephen Moon said the SiS acquisition will accelerate the groups development, with further acquisitions a possibility.

The revenue generating, profitable nature of the new business will help us to achieve our strategic goals, by adding a near term revenue stream to our longer-term pipeline development bias.

In the financial year to December 31 2010, SiS had an unaudited turnover of 4.6m compared with 4.3m in 2009 and an unaudited pre-tax profit of 200,000, against 400,000 the previous year.

Mr Moon said clinical trials for the companys Crohns disease treatment will expand with the opening of four new patient trial centres.

He said the Liverpool R&D team will also investigate the products potential for addressing the so-called superbug C.difficile.

And he said the company has agreed with DSM Nutritional Products, the firm licensed to market Fruitflow, to develop technology for the management of blood glucose.

He added: The management team will be focused on progress in the revenue generating areas of Fruitflow and SiS, while not losing sight of the medium and long term importance of the broader pipeline.

Cash management will continue to be an area of high importance. We will maintain our strategy of developing the capability of the overall Provexis team in line with our goals.

Provexis raised 2.5m in new shares in June and October last year and its cash balance at the end of its latest financial year stands at 7.6m, compared with 7m in 2010.


Read More http://www.liverpooldailypost.co.uk/liverpool-news/regional-news/2011/06/17/provexis-losses-deepen-but-profitable-acquisition-is-added-92534-28894657/#ixzz1PXUUw4wc

cynic your prediction about the plughole looks likely to be coming true.

'fraid so ..... it's total garbage

small read today,Bb, lol

thank you dc....lol not looking good, another seo....long wait.,.

I cannot help that, thats beyond me.

I'm doing my bit but theres only so much you can dlinkk iin aaaaaa ddaaayyyy,,,u undlsand.,.

Have you much invested here